This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Annual Report on Form 10-K filed with the Commission on June 13, 2015 and in Nemaura’s Registration Statement on Form S-3 filed with the Commission on March 18, 2016. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
One platform technology, multiple product applications
Our proprietary technology platform, known as BEAT™, consists of a daily adhesive disposable skin-patch integrated with a reusable Bluetooth-enabled sensor that collects and quantifies a wide range of analytes present within interstitial fluid.
The patch construction and the algorithm that processes the signal to determine glucose levels are our proprietary patented/patent pending technology
Smartphone, Tablet,
Smartwatch or
Optional hand-held reader
Providing full color, high-resolution images of the data, rapidly converted using an algorithm, and displayed in various formats including tabular and graphical
Patch applied to the skin, attached to a slim electronics module containing a highly-sensitive sensor array (combined approximate size 4cm x 3cm x 1cm, with disposable skin-patch measuring 1.5cm x 2cm x 1mm)
In exchange for purchasing $10 million of Nemaura Medical stock (5 million shares), DB Pharma and Nemaura entered into an equal joint venture granting DB an exclusive license to market the sugarBEAT® system across Europe, to commence upon final regulatory approval:
Bashir Timol Director of Business Strategy §Over 10 years’ experience as a business entrepreneur §10 years experience as angel investor in life-science and bio-tech firms §Led initial angel-consortium that provided start-up funding for Nemaura Medical §2013-Present: Director of Business Strategy at Nemaura responsible for financial planning, business and market development and corporate strategies §2007-Present: Director of Nemaura Pharma Ltd §2013-Present: Director of Dermal Diagnostics §2009- Present: Director at SABT 1 Ltd §2009-Present: Director at OneE Group Ltd §Bachelor degree in Economics from the University of Central Lancashire, UK
Madhavi Saharawi Medical Device Advisor §Over 16 years of experience in Quality Assurance and Assurance and Regulatory Affairs (QA & RA) including 14 years plus in Class I to Class III Medical devices, and a former Notified Body Technical File Reviewer §2015-2016: UK &US Director of Regulatory Affairs at Nikon (Optos Plc) §2011 – 2015: Senior Director of QA and RA at Becon and Dickinson (formerly Cardinal Health &CareFusion) §2010 – 2011: Europe Sr. Manager of QA and RA at CareFusion UK (formerly Cardinal Health & Jaeger) §2009 – 2010: Global medical device auditor and QA lead at SGS Notified Body (UK) §2008 – 2009: Manager of QA and RA at t+Medical Limited, UK (a J & J Subsidiary) §2007 – 2008: QA Sr. Engineer at Elekta Oncology Ltd. §2002 – 2006: various positions at Abbott Diabetes UK §Bachelor and Master’s degree from OsmainaUniversity and member of Chartered Quality Institute
Kathryn Farrar Director of Finance §2014-Present: Director of Finance at Nemaura Medical §2010-Present: Financial Manager for Nemaura Pharma Limited, an affiliated company, and is responsible for preparation and management of the accounts of Nemaura Pharma and related companies §1998-2009: KPMG UK §Chartered accountant since 2001 §Received Degree of Masters in Chemistry from University of Oxford